WO1996021655A3 - Inhibiteurs de la calpaine et/ou de la cathepsine b derives d'oxazolidine substituee - Google Patents

Inhibiteurs de la calpaine et/ou de la cathepsine b derives d'oxazolidine substituee Download PDF

Info

Publication number
WO1996021655A3
WO1996021655A3 PCT/US1995/016565 US9516565W WO9621655A3 WO 1996021655 A3 WO1996021655 A3 WO 1996021655A3 US 9516565 W US9516565 W US 9516565W WO 9621655 A3 WO9621655 A3 WO 9621655A3
Authority
WO
WIPO (PCT)
Prior art keywords
calpain
cathepsin
inhibitors
substituted oxazolidine
oxazolidine
Prior art date
Application number
PCT/US1995/016565
Other languages
English (en)
Other versions
WO1996021655A2 (fr
Inventor
Norton P Peet
Shujaath Mehdi
Matthew D Linnik
Michael R Angelastro
Hwa-Ok Kim
Original Assignee
Hoechst Marion Roussel Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NZ298999A priority Critical patent/NZ298999A/xx
Priority to DE69523072T priority patent/DE69523072T2/de
Priority to MX9705235A priority patent/MX9705235A/es
Priority to CA002210258A priority patent/CA2210258C/fr
Priority to JP52166996A priority patent/JP4157601B2/ja
Priority to AU44731/96A priority patent/AU692044B2/en
Priority to DK95943478T priority patent/DK0802909T3/da
Priority to AT95943478T priority patent/ATE206413T1/de
Application filed by Hoechst Marion Roussel Inc filed Critical Hoechst Marion Roussel Inc
Priority to SI9530539T priority patent/SI0802909T1/xx
Priority to EP95943478A priority patent/EP0802909B1/fr
Publication of WO1996021655A2 publication Critical patent/WO1996021655A2/fr
Publication of WO1996021655A3 publication Critical patent/WO1996021655A3/fr
Priority to NO973216A priority patent/NO309267B1/no
Priority to FI972935A priority patent/FI972935A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des inhibiteurs de la calpaïne et/ou de la cathepsine B dérivés d'oxazolidine et des compositions les renfermant. En tant qu'inhibiteurs de la calpaïne et/ou de la cathepsine B, ces composés sont utiles dans le traitement de patients souffrant de troubles neurodégénératifs aigus ou chroniques.
PCT/US1995/016565 1995-01-11 1995-12-15 Inhibiteurs de la calpaine et/ou de la cathepsine b derives d'oxazolidine substituee WO1996021655A2 (fr)

Priority Applications (12)

Application Number Priority Date Filing Date Title
DK95943478T DK0802909T3 (da) 1995-01-11 1995-12-15 Substituerede oxazolidiner som calpain- og/eller cathepsin B-inhibitorer
MX9705235A MX9705235A (es) 1995-01-11 1995-12-15 Inhibidores de calpaina y/o catepsina b de oxazolidina substituida.
CA002210258A CA2210258C (fr) 1995-01-11 1995-12-15 Inhibiteurs de la calpaine et/ou de la cathepsine b derives d'oxazolidine substituee
JP52166996A JP4157601B2 (ja) 1995-01-11 1995-12-15 置換オキサゾリジンカルパインおよび／またはカテプシンｂ阻害剤
AU44731/96A AU692044B2 (en) 1995-01-11 1995-12-15 Substituted oxazolidine calpain and/or cathepsin B inhibitors
NZ298999A NZ298999A (en) 1995-01-11 1995-12-15 4-benzyl-5-hydroxyoxazole derivatives acylated in position-1 by an amino acid, a dipeptide or an acyl group
AT95943478T ATE206413T1 (de) 1995-01-11 1995-12-15 Substituierte oxazolidine als calpain und/oder cathepsin b-hemmer
DE69523072T DE69523072T2 (de) 1995-01-11 1995-12-15 Substituierte oxazolidine als calpain und/oder cathepsin b-hemmer
SI9530539T SI0802909T1 (en) 1995-01-11 1995-12-15 Substituted oxazolidine calpain and/or cathepsin b inhibitors
EP95943478A EP0802909B1 (fr) 1995-01-11 1995-12-15 Inhibiteurs de la calpaine et/ou de la cathepsine b derives d'oxazolidine substituee
NO973216A NO309267B1 (no) 1995-01-11 1997-07-10 Substituerte oxazolidin-calpain- og/eller cathepsin B- inhibitorer og farmasöytisk preparat inneholdende disse
FI972935A FI972935A (fi) 1995-01-11 1997-07-10 Kalpaiinin ja/tai katepsiini B:n substituoituja oksatsolidiiniestäjiä

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37119295A 1995-01-11 1995-01-11
US08/371,192 1995-01-11

Publications (2)

Publication Number Publication Date
WO1996021655A2 WO1996021655A2 (fr) 1996-07-18
WO1996021655A3 true WO1996021655A3 (fr) 1996-09-06

Family

ID=23462894

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/016565 WO1996021655A2 (fr) 1995-01-11 1995-12-15 Inhibiteurs de la calpaine et/ou de la cathepsine b derives d'oxazolidine substituee

Country Status (23)

Country Link
US (1) US5691368A (fr)
EP (1) EP0802909B1 (fr)
JP (1) JP4157601B2 (fr)
KR (1) KR100393701B1 (fr)
CN (1) CN1088456C (fr)
AR (1) AR001787A1 (fr)
AT (1) ATE206413T1 (fr)
AU (1) AU692044B2 (fr)
CA (1) CA2210258C (fr)
DE (1) DE69523072T2 (fr)
DK (1) DK0802909T3 (fr)
ES (1) ES2165441T3 (fr)
FI (1) FI972935A (fr)
HU (1) HUT77649A (fr)
IL (1) IL116724A (fr)
MX (1) MX9705235A (fr)
NO (1) NO309267B1 (fr)
NZ (1) NZ298999A (fr)
PT (1) PT802909E (fr)
SI (1) SI0802909T1 (fr)
TW (1) TW454001B (fr)
WO (1) WO1996021655A2 (fr)
ZA (1) ZA96100B (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1270882B (it) * 1993-10-05 1997-05-13 Isagro Srl Oligopeptidi ad attivita' fungicida
US5925633A (en) * 1996-03-06 1999-07-20 Synphar Laboraties, Inc. 3-Substituted-4-oxa-1-azabicyclo 3,2,0!heptan-7-one as cysteine protease inhibitors
AU6134498A (en) * 1997-03-07 1998-09-22 Hoechst Marion Roussel, Inc. Method of treating trauma associated with brain, spinal cord or peripheral nerveinjury using carbobenzyloxy n-protected di- and tripeptide phenylalaninals
WO2000021550A2 (fr) * 1998-10-13 2000-04-20 President And Fellows Of Harvard College Methodes et compositions de traitement des maladies neurodegeneratives
US6458760B1 (en) * 1998-11-12 2002-10-01 Henry Ford Health System Method for treating tissue damaged from ischemia
WO2000051998A1 (fr) * 1999-03-02 2000-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Composes utiles en tant qu'inhibiteurs reversibles de la cathepsine s
CA2367348A1 (fr) 1999-03-15 2000-09-21 Axys Pharmaceuticals, Inc. Composes et compositions utilises comme inhibiteurs de protease
EP1516877A1 (fr) * 1999-03-15 2005-03-23 Axys Pharmaceuticals, Inc. Derivés d'amine comme inhibiteurs de protease
TW200404789A (en) 1999-03-15 2004-04-01 Axys Pharm Inc Novel compounds and compositions as protease inhibitors
US6420364B1 (en) * 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
FR2800737B1 (fr) * 1999-11-05 2006-06-30 Sod Conseils Rech Applic Nouveaux composes heterocycliques et leur application a titre de medicaments
IL149177A0 (en) * 1999-11-05 2002-11-10 Sod Conseils Rech Applic Novel heterocyclic compounds and their use as medicines
WO2002010768A2 (fr) * 2000-07-31 2002-02-07 The Regents Of The University Of California Modele pour la maladie d'alzheimer et autres maladies neurodegenerative
US7064123B1 (en) 2000-12-22 2006-06-20 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin inhibitors
US7030116B2 (en) 2000-12-22 2006-04-18 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin inhibitors
WO2003024924A1 (fr) 2001-09-14 2003-03-27 Aventis Pharmaceuticals Inc. Nouveaux composes et nouvelles compositions utiles comme inhibiteurs de la cathepsine
HUP0401906A3 (en) 2001-11-14 2008-07-28 Aventis Pharma Inc Novel cathepsin s inhibitors, process for their preparation and pharmaceutical compositions containing them
WO2004084830A2 (fr) * 2003-03-21 2004-10-07 Buck Institute Méthode de traitement de la maladie d'alzheimer
US7109243B2 (en) * 2003-03-24 2006-09-19 Irm Llc Inhibitors of cathepsin S
US7384970B2 (en) * 2003-03-24 2008-06-10 Irm Llc Inhibitors of cathepsin S
WO2004089395A2 (fr) * 2003-04-01 2004-10-21 Aventis Pharmaceuticals Inc. Utilisation d'un inhibiteur de la cathepsine-s ou -b afin de traiter ou de prevenir les maladies pulmonaires obstructives chroniques
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
US7173051B2 (en) * 2003-06-13 2007-02-06 Irm, Llc Inhibitors of cathepsin S
US7256207B2 (en) * 2003-08-20 2007-08-14 Irm Llc Inhibitors of cathepsin S
FR2863268B1 (fr) * 2003-12-09 2006-02-24 Sod Conseils Rech Applic Nouveaux derives du 2-hydroxytetrahydrofuranne et leur application a titre de medicaments
WO2008055945A1 (fr) 2006-11-09 2008-05-15 Probiodrug Ag Dérivés 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one utiles en tant qu' inhibiteurs de la glutaminyl-cyclase dans le traitement des ulcères, du cancer et d'autres maladies
SI2091948T1 (sl) 2006-11-30 2012-07-31 Probiodrug Ag Novi inhibitorji glutaminil ciklaze
ZA200905537B (en) 2007-03-01 2010-10-27 Probiodrug Ag New use of glutaminyl cyclase inhibitors
EP2142514B1 (fr) 2007-04-18 2014-12-24 Probiodrug AG Dérivés de thio-urée utilisés comme inhibiteurs de la glutaminyl cyclase
US20100150938A1 (en) * 2008-07-03 2010-06-17 University Of Massachusetts Methods and compositions for reducing inflammation and treating inflammatory disorders
ES2548913T3 (es) 2009-09-11 2015-10-21 Probiodrug Ag Derivados heterocíclicos como inhibidores de glutaminil ciclasa
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
JP5688745B2 (ja) 2010-03-10 2015-03-25 プロビオドルグ エージー グルタミニルシクラーゼ（ｑｃ、ｅｃ２．３．２．５）の複素環阻害剤
WO2011131748A2 (fr) 2010-04-21 2011-10-27 Probiodrug Ag Nouveaux inhibiteurs
WO2012123563A1 (fr) 2011-03-16 2012-09-20 Probiodrug Ag Dérivés de benzimidazole en tant qu'inhibiteurs de la glutaminyl cyclase
EP3461819B1 (fr) 2017-09-29 2020-05-27 Probiodrug AG Inhibiteurs de la glutaminyl-cyclase
WO2024018245A1 (fr) 2022-07-22 2024-01-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Utilisation d'inhibiteurs de calpaïne pour le traitement de la maladie rénale diabétique

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0275101A2 (fr) * 1987-01-16 1988-07-20 Merrell Dow Pharmaceuticals Inc. Inhibiteurs de peptidases
EP0363284A2 (fr) * 1988-10-07 1990-04-11 Merrell Pharmaceuticals Inc. Utilisation des inhibiteurs de peptidase pour la préparation de médicaments utiles dans le traitement de l'apoplexie
EP0520336A2 (fr) * 1991-06-19 1992-12-30 FUJIREBIO Inc. Composés à fonction aldehyde et leur utilisation comme inhibiteurs de calpain
EP0525420A1 (fr) * 1991-07-01 1993-02-03 Mitsubishi Chemical Corporation Pseudopeptides et peptides caractérisés par une partie méthyle cétone substituée à la terminaison C comme inhibiteurs de thiol protéase
EP0603769A1 (fr) * 1992-12-25 1994-06-29 Mitsubishi Chemical Corporation Dérivés d'alpha-aminocétones
EP0611756A2 (fr) * 1993-02-19 1994-08-24 Takeda Chemical Industries, Ltd. Alcool et aldéhyde dérivés comme inhibiteur de cathepsin L et comme inhibiteur de la résorption osseuse
WO1995000535A1 (fr) * 1993-06-24 1995-01-05 Alkermes, Incorporated Composes inhibiteurs de calpaine optiquement purs

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3867364A (en) * 1968-11-21 1975-02-18 Microbial Chem Res Found Process for the synthesis of leupeptins and their analogues
US5142056A (en) * 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
US4277395A (en) * 1980-06-16 1981-07-07 Richardson-Merrell Inc. Novel enzyme inhibitors
JPS5754157A (en) * 1980-09-19 1982-03-31 Nippon Kayaku Co Ltd L-argininal derivative and its preparation
US4535167A (en) * 1981-12-14 1985-08-13 Merck & Co. Inc. Chiral, N-protected, N-substituted α-amino acids
WO1984000365A1 (fr) * 1982-07-19 1984-02-02 Nat Res Dev Peptides synthetiques et leur preparation
US4845079A (en) * 1985-01-23 1989-07-04 Luly Jay R Peptidylaminodiols
US5091575A (en) * 1985-01-23 1992-02-25 Abbott Laboratories Peptidylaminodiols
US5214129A (en) * 1985-01-23 1993-05-25 Abbott Laboratories Peptidylaminodiols
US5496927A (en) * 1985-02-04 1996-03-05 Merrell Pharmaceuticals Inc. Peptidase inhibitors
JPH079705B2 (ja) * 1986-05-28 1995-02-01 オリンパス光学工業株式会社 光カ−ド用デ−タ記録再生装置
EP0264106B1 (fr) * 1986-10-14 1994-03-16 Banyu Pharmaceutical Co., Ltd. Dérivés 5-substitués de l'acide amino-4-hydroxy-pentanoique et leur emploi
US5032577A (en) * 1986-12-31 1991-07-16 Abbott Laboratories Peptidylaminodiols
US4820691A (en) * 1987-06-24 1989-04-11 E. R. Squibb & Sons, Inc. Amino acid 1,2-diketo derivatives as renin inhibitors
EP0313847A3 (fr) * 1987-10-01 1989-11-29 G.D. Searle & Co. Alpha-succinamidoacyl aminodiols non peptidiques comme agents anti-hypertensifs
EP0397779A1 (fr) * 1988-02-01 1990-11-22 The Upjohn Company Peptides inhibiteur de renine avec groupes terminaux polaires
HUT58764A (en) * 1988-07-08 1992-03-30 Smithkline Beckman Corp Process for producing peptides, pharmaceutical compositions containing them and amino-acid intermediates
US4990525A (en) * 1988-12-22 1991-02-05 Rohm And Haas Company Synergistic microbicidal combinations containing 3-isothiazolone and commerical biocides
JP2701932B2 (ja) * 1989-04-10 1998-01-21 サントリー株式会社 タンパク質分解酵素阻害剤
US5510531A (en) * 1989-04-10 1996-04-23 Suntory Limited Proteinase inhibitor
CA2032259A1 (fr) * 1989-12-18 1991-06-19 Wayne J. Thompson Inhibiteurs de la protease du vih utiles dans le traitement du sida
HUT64738A (en) * 1990-06-01 1994-02-28 Du Pont Merck Pharma Process for preparing 1,4-diamino-2,3-dihydroxi-butane compounds and pharmaceutical compositions contianing them
DE4037437A1 (de) * 1990-11-24 1992-05-27 Hoechst Ag Aminodiol-derivate
US5444042A (en) * 1990-12-28 1995-08-22 Cortex Pharmaceuticals Method of treatment of neurodegeneration with calpain inhibitors
CA2098609A1 (fr) * 1990-12-28 1992-06-29 Raymond T. Bartus Utilisation d'inhibiteurs de la calpaine dans l'inhibition et le traitement de la neurodegenerescence
WO1992012140A1 (fr) * 1990-12-28 1992-07-23 Georgia Tech Research Corporation Cetoamides, cetoacides et cetoesters peptidiques
AU655831B2 (en) * 1991-08-22 1995-01-12 Merrell Pharmaceuticals Inc. Novel orally-active elastase inhibitors
EP0580161A1 (fr) * 1992-07-22 1994-01-26 THE McLEAN HOSPITAL CORPORATION Traitement prophylactique et thérapeutique de la maladie d'Alzheimer
HU221629B1 (hu) * 1993-10-01 2002-12-28 Merrell Pharmaceuticals Inc. Béta-amiloid fehérje képződést gátló peptidek, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0275101A2 (fr) * 1987-01-16 1988-07-20 Merrell Dow Pharmaceuticals Inc. Inhibiteurs de peptidases
EP0363284A2 (fr) * 1988-10-07 1990-04-11 Merrell Pharmaceuticals Inc. Utilisation des inhibiteurs de peptidase pour la préparation de médicaments utiles dans le traitement de l'apoplexie
EP0520336A2 (fr) * 1991-06-19 1992-12-30 FUJIREBIO Inc. Composés à fonction aldehyde et leur utilisation comme inhibiteurs de calpain
EP0525420A1 (fr) * 1991-07-01 1993-02-03 Mitsubishi Chemical Corporation Pseudopeptides et peptides caractérisés par une partie méthyle cétone substituée à la terminaison C comme inhibiteurs de thiol protéase
EP0603769A1 (fr) * 1992-12-25 1994-06-29 Mitsubishi Chemical Corporation Dérivés d'alpha-aminocétones
EP0611756A2 (fr) * 1993-02-19 1994-08-24 Takeda Chemical Industries, Ltd. Alcool et aldéhyde dérivés comme inhibiteur de cathepsin L et comme inhibiteur de la résorption osseuse
WO1995000535A1 (fr) * 1993-06-24 1995-01-05 Alkermes, Incorporated Composes inhibiteurs de calpaine optiquement purs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
P. RADDATZ ET AL.: "Renin Inhibitors Containing New P1-P1' Dipeptide mimetics with Heterocycles in P1'", J. MED. CHEM., vol. 35, no. 19, 1992, pages 3525 - 3536, XP002006249 *

Also Published As

Publication number Publication date
EP0802909B1 (fr) 2001-10-04
IL116724A0 (en) 1996-05-14
DK0802909T3 (da) 2002-01-28
AR001787A1 (es) 1997-12-10
DE69523072T2 (de) 2002-06-20
AU692044B2 (en) 1998-05-28
ZA96100B (en) 1996-07-24
NZ298999A (en) 1999-01-28
IL116724A (en) 2000-08-31
FI972935A0 (fi) 1997-07-10
US5691368A (en) 1997-11-25
CN1088456C (zh) 2002-07-31
SI0802909T1 (en) 2002-02-28
JPH10512257A (ja) 1998-11-24
ATE206413T1 (de) 2001-10-15
DE69523072D1 (en) 2001-11-08
KR100393701B1 (ko) 2003-11-28
CA2210258C (fr) 2002-10-01
HUT77649A (hu) 1998-07-28
WO1996021655A2 (fr) 1996-07-18
PT802909E (pt) 2002-03-28
ES2165441T3 (es) 2002-03-16
JP4157601B2 (ja) 2008-10-01
FI972935A (fi) 1997-07-10
NO309267B1 (no) 2001-01-08
AU4473196A (en) 1996-07-31
NO973216L (no) 1997-09-09
EP0802909A2 (fr) 1997-10-29
MX9705235A (es) 1997-10-31
NO973216D0 (no) 1997-07-10
TW454001B (en) 2001-09-11
CA2210258A1 (fr) 1996-07-18
CN1173174A (zh) 1998-02-11

Similar Documents

Publication Publication Date Title
WO1996021655A3 (fr) Inhibiteurs de la calpaine et/ou de la cathepsine b derives d'oxazolidine substituee
MY117032A (en) A novel compound form.
BR9710994A (pt) Derivados anticonvulsivos úteis no tratamento de obesidade.
WO2004006858A3 (fr) Composes, compositions et methodes d'utilisation de ces derniers
EP1378240A3 (fr) Compositions pharmaceutiques à base d'arsenic pour le traitement du myelome multiple
CA2163361A1 (fr) Derives de substitution de guanidines, agents therapeutiques
WO2004041269A3 (fr) Nouvel emploi pour composition pharmaceutique
CA2199844A1 (fr) Composition pour le traitement d'affections de la peau
TW268937B (fr)
EP0930067A3 (fr) Inhibiteurs de mmp dans le traitement de l'angiogenese oculaire
WO1998036730A3 (fr) Compositions de traitement de l'acne rosacee
DE69838882D1 (de) Pharmazeutisch wirksame verbindungen und methoden zu ihrer anwendung
CA2152771A1 (fr) Derives 7-o-ether de taxane
WO1999012933A3 (fr) Derives de pyrrolopyrrolone en tant qu'inhibiteurs de neutrophile elastase
MXPA94009086A (es) Guanidinas sustituidas terapeuticas.
WO1996022305A3 (fr) Peptides modifies
AU3496295A (en) 2-substituted-4h-3,1-benzoxazin-4-ones and benzthiazin-4-ones as inhibitors of complement clr protease for the treatment of inflammatory processes
WO2000040232A3 (fr) Nouvelles compositions et trousses de bretylium, et leur utilisation dans la prevention et le traitement des pathologies cardio-vasculaires
BG104292A (en) Methods and compositions for the treatment of rheumatoid arthritis
NO20032597L (no) Anvendelse av SARP-1 for behandlingen og/eller forebyggingen av skleroderma
ZA971036B (en) Pharmaceutical compositions for the prevention or treatment of retrovirus infections.
AU2003263978A1 (en) 2',3'-dideoxynucleoside analogues for the treatment or prevention of flavivitridae infections
WO2000047192A3 (fr) COENZYME Qn UTILISE POUR TRAITER LA DOULEUR
CA2294243A1 (fr) Nouvelles cyanoaziridines pour traiter le cancer
DK0495226T3 (da) Anvendelse af 3-aryl-5-alkylthio-4H-1,2,4-triazoler til behandling af hyperrefleksi som følge af spinaltrauma

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 95197320.7

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 298999

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1995943478

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/1997/005235

Country of ref document: MX

Ref document number: 1019970704709

Country of ref document: KR

Ref document number: 972935

Country of ref document: FI

ENP Entry into the national phase

Ref document number: 2210258

Country of ref document: CA

Ref document number: 2210258

Country of ref document: CA

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1995943478

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1019970704709

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1995943478

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1019970704709

Country of ref document: KR